You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The Foundation for Innovative New Diagnostics is tracking commercial coronavirus diagnostics development project, with the goal of guiding procurement.
The firm looks to win new customers among US providers while also partnering with IVD companies to embed its lab data analysis tools in their instruments.
Both deals involve the Inspirata's steps to expand partnerships for its digital pathology solution, the Dynamyx case management platform.
The system, called Galen Prostate, uses a proprietary algorithm to help pathologists detect and grade prostate cancer in biopsies.
The agreement will bring Exalenz's BreathID Breath Test Systems, a urea breath test platform for H. pylori detection, into Meridian's portfolio.
The funds will support the companies' efforts to develop tests for predicting NSCLC patients' response to immunotherapy.
The test is designed to analyze the expression of 17 genes in order to differentiate mild and aggressive forms of Crohn's disease and ulcerative colitis.
Researchers in the US and the United Arab Emirates found that RNA-seq in B-lymphoblastoid cell lines can help identify pathogenic variants that DNA testing missed.
Inspirata said that the partners will combine their digital pathology products to address challenges with traditional pathology testing for H. Pylori.
The partners will evaluate circulating tumor cell-based biomarker panels as potential new tests for use on Ikonisys' Ikoniscope fluorescence microscopy system.